These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 12324987)

  • 1. An overview of insulin glargine.
    Home PD; Ashwell SG
    Diabetes Metab Res Rev; 2002; 18 Suppl 3():S57-63. PubMed ID: 12324987
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Innovative insulins--where do analogues fit?
    Phillips LK; Phillips PJ
    Aust Fam Physician; 2006 Dec; 35(12):969-73. PubMed ID: 17149471
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Insulin therapy in type 2 diabetes: role of the long-acting insulin glargine analogue.
    Yki-Järvinen H
    Eur J Clin Invest; 2004 Jun; 34(6):410-6. PubMed ID: 15200492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Insulin glargine: long-acting basal insulin analog for improved metabolic control.
    Gerich JE
    Curr Med Res Opin; 2004 Jan; 20(1):31-7. PubMed ID: 14741069
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insulin glargine: a new once-daily basal insulin for the management of type 1 and type 2 diabetes mellitus.
    Lam S
    Heart Dis; 2003; 5(3):231-40. PubMed ID: 12783637
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir.
    Peterson GE
    Curr Med Res Opin; 2006 Dec; 22(12):2613-9. PubMed ID: 17166343
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Costs of antihyperglycemic drugs and consumables and treatment satisfaction in patients with type 2 diabetes. Results of the health care research study LIVE-DE (long-acting insulin glargine compared with NPH insulin in Germany)].
    Hauner H; Kohlmann T; Landgraf W; Holle R; Pirk O; Scholten T
    Dtsch Med Wochenschr; 2009 Jun; 134(23):1207-13. PubMed ID: 19472091
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An update on the long-acting insulin analogue glargine.
    Thisted H; Johnsen SP; Rungby J
    Basic Clin Pharmacol Toxicol; 2006 Jul; 99(1):1-11. PubMed ID: 16867163
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of new basal insulin analogues in the initiation and optimisation of insulin therapy in type 2 diabetes.
    Baxter MA
    Acta Diabetol; 2008 Dec; 45(4):253-68. PubMed ID: 18766296
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational use of insulin analogues in the treatment of type 1 diabetes mellitus.
    Bolli GB
    Pediatr Endocrinol Rev; 2003 Sep; 1(1):9-21. PubMed ID: 16437009
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials.
    Bazzano LA; Lee LJ; Shi L; Reynolds K; Jackson JA; Fonseca V
    Diabet Med; 2008 Aug; 25(8):924-32. PubMed ID: 18959605
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis.
    Monami M; Marchionni N; Mannucci E
    Diabetes Res Clin Pract; 2008 Aug; 81(2):184-9. PubMed ID: 18495286
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment with insulin glargine does not suppress serum IGF-1.
    Slawik M; Schories M; Busse Grawitz A; Reincke M; Petersen KG
    Diabet Med; 2006 Jul; 23(7):814-7. PubMed ID: 16842489
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study.
    Schöffski O; Breitscheidel L; Benter U; Dippel FW; Müller M; Volk M; Pfohl M
    J Med Econ; 2008; 11(4):695-712. PubMed ID: 19450076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Insulin analogues: place of detemir (Levemir)].
    Dorchy H; Sternon J
    J Pharm Belg; 2006; 61(2):58-62. PubMed ID: 16866083
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Insulin glargine maintains equivalent glycemic control and better lipometabolic control than NPH insulin in type 1 diabetes patients who missed a meal.
    Rosak C; Jung R; Hofmann U
    Horm Metab Res; 2008 Aug; 40(8):544-8. PubMed ID: 18493882
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Insulin glargine and receptor-mediated signalling: clinical implications in treating type 2 diabetes.
    Le Roith D
    Diabetes Metab Res Rev; 2007 Nov; 23(8):593-9. PubMed ID: 17922476
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Observational, open-label study of type 1 and type 2 diabetes patients switching from human insulin to insulin analogue basal-bolus regimens: insights from the PREDICTIVE study.
    Hermansen K; Dornhorst A; Sreenan S
    Curr Med Res Opin; 2009 Nov; 25(11):2601-8. PubMed ID: 19739940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the subcutaneous absorption of insulin glargine (Lantus) and NPH insulin in patients with Type 2 diabetes.
    Luzio SD; Beck P; Owens DR
    Horm Metab Res; 2003 Jul; 35(7):434-8. PubMed ID: 12931275
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Long-acting insulin analogs: progressing slowly].
    Holleman F; Hoekstra JB
    Ned Tijdschr Geneeskd; 2004 Aug; 148(34):1668-9. PubMed ID: 15453117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.